睿昂基因(688217) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥34,355,268.37, a decrease of 37.35% compared to the same period last year[4] - The total profit for the third quarter was -¥13,160,358.53, with a year-to-date total profit of -¥16,512,859.59[4] - The net profit attributable to shareholders for the third quarter was -¥9,174,959.22, representing a 198.14% increase in losses year-to-date[4] - Total operating revenue for the first three quarters of 2025 was CNY 139,103,619.10, a decrease of 26.6% compared to CNY 189,630,100.09 in the same period of 2024[21] - Net profit for the first three quarters of 2025 was a loss of CNY 12,308,952.88, compared to a profit of CNY 1,547,536.52 in the same period of 2024[22] - The company reported a basic and diluted earnings per share of CNY -0.10 for the first three quarters of 2025, compared to CNY 0.10 in 2024[23] - Basic and diluted earnings per share for the third quarter were both -¥0.17, a decrease of 200% compared to the previous year[5] Research and Development - Research and development expenses totaled ¥10,801,929.03 for the quarter, accounting for 31.44% of operating revenue, an increase of 8.37 percentage points[5] - Research and development expenses for the first three quarters of 2025 were CNY 42,449,127.26, down 9.7% from CNY 46,854,439.70 in 2024[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥947,826,923.07, a decrease of 3.84% from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥440,132,705.37, a decrease from ¥470,136,956.05 as of December 31, 2024[17] - Total assets amount to ¥947,826,923.07, down from ¥985,701,603.79[17] - The total liabilities decreased to CNY 39,491,403.37 in 2025 from CNY 65,057,131.21 in 2024, reflecting a reduction of 39.2%[19] - The total equity attributable to shareholders decreased to CNY 903,635,431.60 in 2025 from CNY 909,256,093.84 in 2024, a decline of 0.7%[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥26,861,231.93, a decrease of 17.60% compared to the previous year[4] - The company's cash flow from operating activities for the first three quarters of 2025 was CNY 156,046,434.85, a decrease of 19.8% from CNY 194,589,393.22 in 2024[25] - The net cash flow from operating activities was $26,861,231.93, a decrease of 17.4% compared to $32,599,551.94 in the previous period[26] - Total cash inflow from investment activities was $154,094,855.46, down from $181,198,809.30, reflecting a decline of 15%[26] - The net cash flow from investment activities was -$30,164,097.45, an improvement from -$36,834,773.43 in the previous period[26] - Cash outflow from financing activities totaled $18,199,331.59, slightly decreased from $19,766,138.25[27] - The net increase in cash and cash equivalents was -$21,961,958.45, compared to -$24,532,157.77 in the previous period[27] - Cash outflow for purchasing goods and services was $31,790,293.19, compared to $37,921,991.98 previously, indicating a decrease of 16.5%[26] - Cash paid to employees was $60,546,569.70, down from $70,624,800.75, a reduction of 14.4%[26] - Cash paid for taxes increased to $17,337,356.89 from $11,673,215.72, representing a rise of 48.5%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,715[12] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, representing 18.22% of total shares[12] Impairment and Competition - The company reported an increase in accounts receivable credit impairment losses by 30.92% year-on-year, amounting to ¥5,052,650[10] - The company experienced a significant increase in credit impairment losses, which rose to CNY -7,222,974.28 in 2025 from CNY -5,517,111.95 in 2024[22] - The company experienced intensified competition in the in vitro diagnostics industry, impacting revenue negatively[9] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[28]